Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein (LDL) cholesterol when added to statin treatment. However, the effect of ezetimibe on the progression of atherosclerosis remains unknown. METHODS: We conducted a double-blind, randomized, 24-month trial comparing the effects of daily therapy with 80 mg of simvastatin either with placebo or with 10 mg of ezetimibe in 720 patients with familial hypercholesterolemia. Patients underwent B-mode ultrasonography to assess the intima-media thickness of the walls of the carotid and femoral arteries. The primary outcome measure was the change in the mean carotid-artery intima-media thickness, which was defined as the average of the means of the far-wall intima-media thickness of the right and left common carotid arteries, carotid bulbs, and internal carotid arteries. RESULTS: The primary outcome, the mean (+/-SE) change in the carotid-artery intima-media thickness, was 0.0058+/-0.0037 mm in the simvastatin-only group and 0.0111+/-0.0038 mm in the simvastatin-plus-ezetimibe (combined-therapy) group (P=0.29). Secondary outcomes (consisting of other variables regarding the intima-media thickness of the carotid and femoral arteries) did not differ significantly between the two groups. At the end of the study, the mean (+/-SD) LDL cholesterol level was 192.7+/-60.3 mg per deciliter (4.98+/-1.56 mmol per liter) in the simvastatin group and 141.3+/-52.6 mg per deciliter (3.65+/-1.36 mmol per liter) in the combined-therapy group (a between-group difference of 16.5%, P<0.01). The differences between the two groups in reductions in levels of triglycerides and C-reactive protein were 6.6% and 25.7%, respectively, with greater reductions in the combined-therapy group (P<0.01 for both comparisons). Side-effect and safety profiles were similar in the two groups. CONCLUSIONS: In patients with familial hypercholesterolemia, combined therapy with ezetimibe and simvastatin did not result in a significant difference in changes in intima-media thickness, as compared with simvastatin alone, despite decreases in levels of LDL cholesterol and C-reactive protein. (ClinicalTrials.gov number, NCT00552097 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the earlier ENHANCE trial could not confirm that an addition of ezetimibe to statins significantly reduces intima-media thickness in patients with familial hypercholesterolemia, the SHARP and SEAS trials highlight ezetimibe’s role in the prevention of ischaemic cardiovascular events [62–65].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [65]
In the citing paper
“the SHARP and SEAS trials highlight ezetimibe’s role in the prevention of ischaemic cardiovascular events [62–65].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [65]
Citations
Cites
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationBots, M. L., Hoes, A. W., Koudstaal, P. J., Hofman, A., & Grobbee, D. E. (1997) · Circulation · doi:10.1161/01.cir.96.5.1432 · Cited by 2,345
Self-citationNiemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,577
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Self-citationBuchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231404 · Cited by 1,001
Smilde, T., van Wissen, S., Awollersheim, H., Trip, M., Kastelein, J., & Stalenhoef, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04053-8 · Cited by 918
Self-citationTaylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K., & Grace, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000148955.19792.8d · Cited by 890
The safety of statins in clinical practice
Armitage, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60716-8 · Cited by 833
Cited by
Items 701–800 of 1,000
Emerging Therapies for Atherosclerosis Prevention and Management
Chyu, K., & Shah, P. K. (2010) · Cardiology Clinics · doi:10.1016/j.ccl.2010.10.003 · Cited by 8
“In patients with familial hypercholesterolemia, ezetimibe produced a significant reduction in LDL-C when combined with 80 mg simvastatin, compared with simvastatin alone, and was well tolerated.(15) Ezetimibe is a welcome addition to our armamentarium as monotherapy for patients who need modest LDL lowering or as comb…”
BackgroundResultAlmanac 2015: coronary artery disease
Shavelle, D. M. (2016) · Heart · doi:10.1136/heartjnl-2015-307761 · Cited by 9
Gould, A. L., Koglin, J., Bain, R. P., Pinto, C. A., Mitchel, Y., Pasternak, R. C., & Sapre, A. (2009) · Clinical Trials · doi:10.1177/1740774509339977 · Cited by 8
“Earlier studies used averages of the maximal cIMT measures [24,26] whereas more recent studies shifted to averages of the mean cIMT as primary study endpoints [7,12].”
BackgroundMethodInfluentialEfficacy and safety of ezetimibe plus atorvastatin therapy
Foody, J. M., Toth, P. P., Tershakovec, A. M., Musliner, T., Tomassini, J. E., Lowe, R. S., Neff, D., & Davis, H. R. (2014) · Clinical Lipidology · doi:10.2217/clp.14.36 · Cited by 11
Villa, J., & Pratley, R. E. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0107-5 · Cited by 8
“In 2008, the ENHANCE study demonstrated no difference between ezetimibe/simvastatin compared with simvastatin alone on carotid artery intima-media thickness in patients with familial hypercholesterolemia [5].”
BackgroundSun, H., Yuan, Y., Wang, P., Cai, R., Xia, W., Huang, R., & Wang, S. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0147-6 · Cited by 8
“For example, according to previous reports, all patients with peripheral arterial disease or those with familial hypercholesterolemia benefit from the intensified LDL-c target of statin therapy [31, 32].”
ResultHo, H.-C., Chen, M.-F., Hwang, J., Lee, Y., & Su, T. (2009) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.836 · Cited by 9
Strony, J. T., Yang, B., Hanson, M. E., & Veltri, E. P. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802426581 · Cited by 8
Self-citationNew insights in preventive cardiology and cardiac rehabilitation
Franklin, B. A., Trivax, J. E., & Vanhecke, T. E. (2008) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32830b360b · Cited by 8
Robinson, J. G., & Davidson, M. H. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.6.781 · Cited by 8
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Steinberg, D. H. (2008) · New England Journal of Medicine · doi:10.1056/nejmc080981 · Cited by 9
A review on the efficacy and safety of lipid-lowering drugs in neurodegenerative disease
Rajabian, A., McCloskey, A. P., Jamialahmadi, T., Moallem, S. A., & Sahebkar, A. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2023-0005 · Cited by 7
Cardiometabolic Impact of Non-Statin Lipid Lowering Therapies
Goyal, P., Igel, L. I., LaScalea, K., & Borden, W. B. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0390-0 · Cited by 7
Importance of early recognition of heterozygous familial hypercholesterolaemia
Ryan, A., & Byrne, C. D. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000196 · Cited by 7
“However, a randomized control trial studying the combination of ezetimbie with a statin failed to detect a difference in carotid intima– media thickness, compared with statin alone [37].”
BackgroundRepurposing of Various Current Medicines as Radioprotective Agents
Kaur, R., Lang, D. K., Singh, H., Arora, A., Garg, N., & Saini, B. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220404090049 · Cited by 8
Obesity, the Endocannabinoid System, and Bias Arising from Pharmaceutical Sponsorship
McPartland, J. M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005092 · Cited by 9
“Serum cholesterol serves as a surrogate for cardiovascular disease, and ezetimibe-simvastatin lowers serum cholesterol, but ezetimibe-simvastatin did not slow the development of atherosclerosis in patients [41].”
BackgroundStandl, E. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112448876 · Cited by 7
Implications of recent clinical trials on pay-for-performance
Gellad, W. F., Detsky, A. S., & Choudhry, N. K. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080577 · Cited by 8
The past, present and future of lipidlowering therapy
Najam, O., Lambert, G. C., & Ray, K. K. (2015) · Clinical Lipidology · doi:10.2217/clp.15.40 · Cited by 7
Jackowska, P., Pytel, E., Koter−Michalak, M., Olszewska-Banaszczyk, M., Legęza, A., & Broncel, M. (2016) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/34791 · Cited by 7
Young, E. P., & Stitziel, N. O. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-041717-085853 · Cited by 7
Kurbanoğlu, S., Eşim, Ö., Özkan, C. K., Savaşer, A., Özkan, Y., & Özkan, S. A. (2018) · Chromatographia · doi:10.1007/s10337-018-3642-x · Cited by 7
Huang, Z., Li, Q., Ye, W., Zhang, Q., & Li, X. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c18-00685 · Cited by 7
Sun, F., Liu, Y., Li, T., Lin, P., Jiang, X., Li, X., Wang, C., Gao, X., Ma, Y., Fu, Y. S., et al. (2023) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-023-00649-y · Cited by 8
Kwon, R. J., Cho, Y. H., Park, E. J., Lee, Y., Lee, S. R., Choi, J. I., Lee, S. Y., & Son, S. M. (2023) · Medicina · doi:10.3390/medicina59111980 · Cited by 8
Clinical imaging in anti-atherosclerosis drug development
Ehlgen, A., Bylock, A. L., Kreuzer, J., Koslowski, M., Gantner, F., & Niessen, H. G. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.06.014 · Cited by 9
Shay, C., Evans, R. W., & Orchard, T. (2009) · Journal of Diabetes · doi:10.1111/j.1753-0407.2009.00012.x · Cited by 12
Bays, H. E., Chen, E., Tomassini, J. E., McPeters, G., Polis, A. B., & Triscari, J. M. (2014) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12096 · Cited by 7
Significance of LDL-C lowering therapy in diabetic patients
Martinez-Hervas, M. S., Carmena, M. R., & Ascaso, M. J. F. (2011) · Clinical Lipidology · doi:10.2217/clp.11.28 · Cited by 7
Kotlęga, D., Ciećwież, S. M., Turowska-Kowalska, J., & Nowacki, P. (2012) · Neurologia i Neurochirurgia Polska · doi:10.5114/ninp.2012.28261 · Cited by 10
“Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia) wykazano, ¿e zastosowanie simwastatyny w monoterapii opóŸnia wzrost gruboœci IMT [22].”
InfluentialEzetimibe and Vascular Endothelial Function
Ikeda, S., & Maemura, K. (2010) · Current Vascular Pharmacology · doi:10.2174/157016111793744797 · Cited by 7
“Two large, long-term trials of ezetimibe, in which the primary outcome was designated as a change in carotid intima-media thickness (CIMT), have recently been published: the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) [126] and Stop Atherosclerosis in Native Diabetic…”
BackgroundSurrogate End Points in Secondary Analyses of Cardiovascular Trials
Buhr, K. A. (2012) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2011.09.007 · Cited by 8
Ezetimibe and recent clinical trials: a look on the bright side
Ahmed, M. H. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740331003702376 · Cited by 7
Dyslipidemia Part 2: Review of Dyslipidemia Treatment in Patients With Noncoronary Vascular Disease
Gonzalez, L., Helkin, A. W., & Gahtan, V. (2016) · Vascular and Endovascular Surgery · doi:10.1177/1538574416628655 · Cited by 8
Carotid intima-media thickness: more than a research tool?
Verhamme, P. B., Kerkhof, F., Buysschaert, I., Rietzschel, E. R., & de Groot, E. (2010) · Acta Cardiologica · doi:10.2143/ac.65.1.2045890 · Cited by 8
Möglichkeiten und Grenzen der modernen Lipidtherapie
Klose, G. (2011) · Der Internist · doi:10.1007/s00108-010-2799-7 · Cited by 7
Pauriah, M., Struthers, A. D., & Lang, C. C. (2008) · Cardiovascular Therapeutics · doi:10.1111/j.1527-3466.2008.00048.x · Cited by 7
“The recent publication of the disappointing results of the ENHANCE study (Kastelein et al. 2008) in which the simvastatin-ezetemibe 80/10 mg combination, when compared to simvastatin 80 mg alone, failed to show the expected decrease in carotid intima media thickness (CIMT) despite greater reductions in LDL-cholesterol…”
ResultRole of ezetimibe in the management of patients with atherosclerosis
Hamilton, P. (2009) · Coronary Artery Disease · doi:10.1097/mca.0b013e32831edd4c · Cited by 7
Impact of Medical Therapy on Atheroma Volume Measured by Different Cardiovascular Imaging Modalities
Sinno, M., & Al-Mallah, M. H. (2010) · Cardiology Research and Practice · doi:10.4061/2010/134564 · Cited by 7
Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy
Sterling, J. A. (2007) · Hospital Pharmacy · doi:10.1310/hpj4206-578 · Cited by 7
Metformin: An Old Drug with New Tricks—Promising Role in Vascular Aging and Cardioprotection
Sivakumar, R., Senghor, K. A. A., Vinodhini, V. M., & Kumar, J. S. (2025) · Drugs & Aging · doi:10.1007/s40266-025-01215-3 · Cited by 7
Drexel, H., Festa, A., Schmidt, T. A., Rocca, B., Dobrev, D., Agewall, S., Tamargo, J. L., & Kaser, S. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf076 · Cited by 7
Advances in familial hypercholesterolemia
Paquette, M., & Baass, A. W. (2024) · Advances in clinical chemistry · doi:10.1016/bs.acc.2024.02.004 · Cited by 6
Redefining Macrophage Heterogeneity in Atherosclerosis: A Focus on Possible Therapeutic Implications
Kanuri, B., Maremanda, K. P., Chattopadhyay, D., Essop, M. F., Lee, M. K. S., Murphy, A. J., & Nagareddy, P. R. (2025) · Comprehensive physiology · doi:10.1002/cph4.70008 · Cited by 7
“Furthermore, assessment of carotid intima-media thickness indicated that ezetimibe addition to background statin therapy failed to prevent atherogenic progression (Kastelein et al. 2008).”
Role of Ezetimibe in the Prevention of Cardiovascular Disease: Absence of Evidence
Mascitelli, L., Pezzetta, F., & Goldstein, M. R. (2010) · Archives of Medical Research · doi:10.1016/j.arcmed.2010.10.008 · Cited by 6
Ultrasound and radiology surrogate endpoints in pharmacological studies
Agewall, S., deGroot, E., Marcos‐Alberca, P., Zamorano, J. L., Barrero, A. A., Badano, L. P., & Filardi, P. P. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.03.038 · Cited by 6
Self-citationVosper, H. (2011) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s7601 · Cited by 6
The hinterland of familial hypercholesterolaemia: what do we not know?
Wierzbicki, A. S., & Watts, G. F. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000238 · Cited by 7
“the controversial Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) the addition of ezetimibe to baseline simvastatin 80 mg in a group of mostly statin pretreated familial hypercholesterolaemia patients had no effect on cIMT [75].”
BackgroundCombined Phytosterol and Fish Oil Therapy for Lipid Lowering and Cardiovascular Health
Phang, M., & Garg, M. L. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-404610-8.00016-5 · Cited by 6
Fließer, E., Jandl, K., Chen, S.-H., Wang, M.-T., Schupp, J. C., Kuebler, W. M., Baker, A. H., & Kwapiszewska, G. (2025) · JCI Insight · doi:10.1172/jci.insight.191059 · Cited by 7
“Statins have demonstrated good results in reducing inflammation (190, 191).”
Fahed, A. C., Habib, R., Nemer, G. M., Azar, S. T., Andary, R. R., Arabi, M. T., Moubarak, E. M., Bitar, F. F., & Haddad, F. (2013) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2013.02.024 · Cited by 6
Critical review of non-statin treatments for dyslipoproteinemia
Pang, J., Chan, D. C., & Watts, G. F. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.888312 · Cited by 7
“A study in statin-treated FH subjects showed no differences in intima-media thickness with adjunctive ezetimibe in spite of a reduction in plasma LDL cholesterol concentrations [125].”
BackgroundEzetimibe: Clinical and Scientific Meaning of the IMPROVE-IT Study
Correia, L. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160033 · Cited by 6
Punekar, R. S., Fox, K. M., Paoli, C. J., Richhariya, A., Cziraky, M. J., Gandra, S. R., & Toth, P. P. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1292898 · Cited by 6
Sisson, E. M., Pamulapati, L. G., Bucheit, J. D., Kelly, M. S., & Dixon, D. L. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2074 · Cited by 6
Extracranial Carotid Duplex Ultrasonography. Part II - Clinical Utility of Carotid Duplex Ultrasound
Lee, J. Y., Choi, H., Lee, S. I., Hwang, Y., Cho, A.-H., Seo, W.-K., Lee, S., Yu, S., Hong, J. M., Ahn, S. H., et al. (2018) · Journal of Neurosonology and Neuroimaging · doi:10.31728/jnn.2018.00025 · Cited by 6
“ENHANCE 연구는 simvastatin 80 mg + ezetimibe 10 mg의 병합요법 과 simvastatin 80 mg의 단독요법이 내중막두께에 미치는 영 향을 비교한 것이다.(92) 조기 관상동맥질환의 위험이 높고 유년 기부터 내중막두께 증가속도가 높은 720명의 가족성 고콜레스 테롤혈증 환자를 대상으로 2년간 일차종결목표인 내중막두께 를 서로 비교하였다.”
A sustainable catalytic enantioselective synthesis of norstatine derivatives
Shi, T., Jing, C., Qian, Y., Xu, X., Reddy, A. G. K., Lv, X., & Hu, W. (2019) · Organic & Biomolecular Chemistry · doi:10.1039/c9ob02149c · Cited by 6
Konstandin, M. H., Blessing, E., Doesch, A. O., Ammon, K., Koch, A., Wabnitz, G. H., Gleissner, C. A., Remppis, A., Katus, H. A., & Dengler, T. J. (2008) · Clinical Transplantation · doi:10.1111/j.1399-0012.2008.00838.x · Cited by 8
“Recently, data of the ENHANCE trial have shown no beneficial effect of the addition of ezetimibe to simvastatin medication on carotid intima-media thickness as a surrogate marker for atherosclerotic burden in patients with familial hypercholesterolemia (26), while clinical endpoints (mortality, myocardial infarction,…”
BackgroundHalcox, J. (2013) · Clinical Lipidology · doi:10.2217/clp.13.16 · Cited by 6
Schwab, P., Louder, A. M., Li, Y., Mallick, R., & Bays, H. E. (2014) · Drugs & Aging · doi:10.1007/s40266-014-0200-6 · Cited by 6
“Median [IQR] 68 [18–89] 68 [32–89]”
BackgroundInhibition of PCSK9 in familial hypercholesterolaemia
Sijbrands, E. J. G. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60814-9 · Cited by 6
Self-citationAdjunctive Lipid Lowering Therapy in the Era of Surrogate Endpoints
Silverman, M. G., Blaha, M. J., & Blumenthal, R. S. (2010) · Cardiology in Review · doi:10.1097/crd.0b013e3181fc212a · Cited by 7
“When used in combination, ezetimibe provides an additional 16% to 21% LDL-C reduction on top of statin therapy.(17,18) Ezetimibe works through inhibition of cholesterol absorption in the small intestine by selective antagonism of the Niemann-Pick C1-like 1 protein (transporter responsible for the uptake and transport…”
BackgroundMethodPCSK9 inhibitors in familial hypercholesterolemia: What is the evidence?
Paquette, M., Hegele, R. A., & Baass, A. W. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.05.010 · Cited by 6
Novel and Emerging Therapeutics for Primary Prevention of Cardiovascular Disease
Buckley, L. F., Carbone, S., Aldemerdash, A. M., Fatani, N., & Fanikos, J. R. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.08.019 · Cited by 7
Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle
Shek, A. B., Alieva, R. B., Kurbanov, R. D., Hoshimov, S. U., Nizamov, U. I., Abdullaeva, G., & Nagay, A. V. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.08.016 · Cited by 6
Baruch, L., Gupta, B. P., Lieberman-Blum, S. S., Agarwal, S., & Eng, C. (2008) · PubMed · Cited by 7
Clever, Y. P., Rosenkranz, S., Böhm, M., & Scheller, B. (2008) · Clinical Research in Cardiology · doi:10.1007/s00392-008-0672-7 · Cited by 6
Biomarkers, Atherosclerosis and Cardiovascular Events
Rosenson, R. S. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.5.619 · Cited by 6
Maio, A., & Dowd, F. J. (2008) · Elsevier eBooks · doi:10.1016/b978-008055232-3.60629-4 · Cited by 6
MR Imaging-Verified Plaque Delipidation With Lipid-Lowering Therapy
Kramer, C. M., Mani, V., & Fayad, Z. A. (2011) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2011.06.014 · Cited by 6
Is There a Problem With Ezetimibe or Just ENHANCEd Hype?
Whayne, T. F. (2008) · Angiology · doi:10.1177/0003319708321188 · Cited by 6
“Additionally, there were no significant differences in cardiovascular outcomes between the 2 groups.(1) Also, it is intriguing that group 1 with ezetimibe/simvastatin resulted in a 25.”
BackgroundMethodPirillo, A., & Catapano, A. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809657-4.99567-x · Cited by 6
Henry, D., Baugé, E., Staels, B., & Lalloyer, F. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100086 · Cited by 5
Walker, M., Riggs, K. A., Rohatgi, A. K., Beckman, J. A., Addo, T. A., Girotra, S. R., Bonaca, M. P., Armstrong, E. J., & Kumbhani, D. J. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.039734 · Cited by 5
“91 However, in a secondary analysis of IMPROVE-IT, individuals with coronary artery disease and polyvascular disease had additive long-term cardiovascular risk of the primary end point of cardiovascular death, major coronary event (nonfatal MI, documented unstable angina requiring hospital…”
Al-Siyabi, K., Farhan, H., Al‐Rasadi, K., Al-Salhi, A., Al-Hinai, A. T., & Al-Zakwani, I. S. (2010) · Oman Medical Journal · doi:10.5001/omj.2010.79 · Cited by 6
Huang, X., & Chen, D. Y. ‐. (2012) · ChemMedChem · doi:10.1002/cmdc.201200287 · Cited by 5
Emerging drugs for hyperlipidaemia: an update
Florentin, M., Kostapanos, M. S., Kei, A. A., & Elisaf, M. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.976553 · Cited by 5
“Promising medications failed to demonstrate clinical benefit or were associated with deleterious outcomes [5,6].”
BackgroundRiccioni, G., Cipollone, F., Santovito, D., Scotti, L., D’Orazio, N., Mezzetti, A., & Bucciarelli, T. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.618497 · Cited by 5
“Starting from this observation, some trials tested a ‘normal’ versus an ‘aggressive’ LDL-C-lowering strategy on cIMT progression, including the ASAP (atorvastatin and simvastatin on atherosclerosis progression) [19] and the ARBITER (arterial biology for the investigation of the treatment effects of reducing cholestero…”
BackgroundInfluentialEnhanced identification of familial hypercholesterolemia using central laboratory algorithms
Ibrahim, S., Nurmohamed, N. S., Nierman, M. C., de Goeij, J. N., Zuurbier, L. C., van Rooij, J., Schonck, W. A. M., de Vries, J., Hovingh, G. K., Reeskamp, L. F., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117548 · Cited by 7
Self-citationChallenge of Surrogate Endpoints
Furgerson, J. L., Hannah, W. N., & Thompson, J. C. (2012) · Southern Medical Journal · doi:10.1097/smj.0b013e318249891e · Cited by 5
“A subsequent clinical trial using carotid intima media thickness (CIMT) as a measure of atherosclerotic plaque burden found, however, that there was no improvement in plaque progression with ezetimibe when added to statin therapy versus statin therapy alone, despite a significant decrease in LDL associated with ezetim…”
BackgroundMethodInfluence of Previous Statin Therapy on Cholesterol-Lowering Effect of Ezetimibe
Choi, Y. H., Kim, Y., Hyeon, C. W., Hyun, S., Kwon, J. E., Won, H., Shin, S. Y., Lee, W. S., Lee, K. J., Kim, S., et al. (2014) · Korean Circulation Journal · doi:10.4070/kcj.2014.44.4.227 · Cited by 5
Evaluating Lipid-Lowering Trials in the Twenty-First Century
Roberts, W. C. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.02.008 · Cited by 5
Dyslipidemia: Pathogenesis and Management
Ganda, O. P. (2009) · Springer eBooks · doi:10.1007/978-0-387-09841-8_28 · Cited by 5
Toth, P. P. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-963-5_3 · Cited by 5
Prospective cardiac gating of carotid three‐dimensional ultrasound
Mallett, C. L., Gardi, L., Fenster, A., & Párraga, G. (2009) · Medical Physics · doi:10.1118/1.3134243 · Cited by 5
Höglund, N., Andersson, J. S. O., Almroth, H., Tornvall, P., Englund, A., Rosenqvist, M., Jensen, S. M., & Boman, K. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.05.071 · Cited by 5
“Several studies have shown that statin treatment reduces plasma markers of inflammation [7,8,14–17].”
BackgroundPrevención primaria farmacológica en hipertensión arterial y dislipemias
González‐Juanatey, J. R., & Mazón‐Ramos, P. (2008) · Revista Española de Cardiología · doi:10.1157/13124997 · Cited by 8
Clinical Management Considerations for Dyslipidemia in HIV–Infected Individuals
Kirchner, J. T. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.01.2515 · Cited by 5
Ethical Issues in New Drug Prescribing
Cole, L. W., Kesselheim, J. C., & Kesselheim, A. S. (2011) · Journal of Bioethical Inquiry · doi:10.1007/s11673-011-9342-y · Cited by 5
Effect of plant sterols compared with ezetimibe on oxidative stress in patients treated with statins
Bertolami, A., Botelho, P. B., Macedo, L. F. L., Abdalla, D. S. P., Faludi, A. Á., Galasso, M., & de Castro, I. A. (2014) · Journal of Functional Foods · doi:10.1016/j.jff.2014.05.018 · Cited by 5
LIPID‐LOWERING THERAPY IN CHRONIC KIDNEY DISEASE: IS THERE A ROLE FOR EZETIMIBE?
Green, D., Panayotova, R., Ritchie, J. P., O’Riordan, E., & McDonald, J. (2012) · Journal of Renal Care · doi:10.1111/j.1755-6686.2012.00309.x · Cited by 5
Chan, D. C., Pang, J., & Watts, G. F. (2015) · Springer eBooks · doi:10.1007/978-3-319-12125-3_30-1 · Cited by 7
Cameron, S., Daimee, U. A., & Block, R. C. (2015) · PubMed · Cited by 5
Wang, C., Wang, F., Cao, Q., Li, Z., Huang, L., & Chen, S. (2018) · Aging Medicine · doi:10.1002/agm2.12032 · Cited by 6
Orringer, C. E. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.04.009 · Cited by 5
Nezhadebrahimi, A., Sepehri, H., Jahanshahi, M., Marjani, M., & Marjani, A. (2020) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2020.1772829 · Cited by 5
“Some studies have been indicated that there is an association between simvastatin and a high-fat diet to reveal to prevent or reduce risks of cardiovascular disease (Kastelein et al. 2008).”
BackgroundLipid-modifying and antiatherosclerotic drugs
Gotto, A. M., & Opie, L. H. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-3322-4.00019-3 · Cited by 6
Atherosclerosis surrogate imaging trials come of age: For better or for worse?
Davidson, M. H., & Dembowski, E. (2008) · Current Cardiology Reports · doi:10.1007/s11886-008-0081-6 · Cited by 5
Efficacy and Safety of Ezetimibe for Japanese Patients with Dyslipidaemia: The ESSENTIAL Study
Sawayama, Y., Maeda, S., Ohnishi, H., Hayashi, S., & Hayashi, J. (2010) · Clinical Drug Investigation · doi:10.2165/11531530-000000000-00000 · Cited by 5
Is There Evidence-based Hypolipidemic Treatment with Clinical Benefit beyond Statins?
Goumas, G. S. (2008) · Angiology · doi:10.1177/0003319708326452 · Cited by 6
Metadata
- Authors
- Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., Gaudet, D., Duivenvoorden, R., Veltri, E. P., Marais, A. D., & de Groot, E.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- University Medical Center Utrecht (NL)
- Radboud University Nijmegen (NL)
- Erasmus MC (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-04-03
- Volume
- 358
- Issue
- 14
- Pages
- 1431-1443
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2120289695
- Semantic Scholar
- 0da4a48a4d402878a4b01330a3e43a185140f586
- Cited by
- 1,241
- References
- 34
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 16 · 2023: 20 · 2022: 14 · 2021: 24 · 2020: 27 · 2019: 35 · 2018: 30 · 2017: 38 · 2016: 50 · 2015: 77 · 2014: 91 · 2013: 85 · 2012: 111
- FWCI
- 210.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- simvastatin, ezetimibe, familial hypercholesterolemia, LDL cholesterol lowering, atherosclerosis progression, carotid intima-media thickness, femoral artery, cholesterol absorption inhibition, triglycerides, C-reactive protein, statin combination therapy, lipid-lowering therapy, atherosclerotic plaque regression
- MeSH terms
- Ezetimibe, Adult, Anticholesteremic Agents, Azetidines, Carotid Arteries, Cholesterol, Double-Blind Method, Drug Therapy, Combination, Female, Femoral Artery, Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Male, Middle Aged, Triglycerides, Ultrasonography, Treatment Outcome, Tunica Intima, Tunica Media, Simvastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.